Saturday 17 October 2026
Export GKOS’s income statement to Excel — free account
Glaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024. In the quarter to June 2026, revenue grew 49.5%, EPS grew 8.82%, free cash flow grew 211.8% and total debt fell 2.15%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
164.84
0.76
−0.46%
Follow GKOS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
13.41 | 11.33 | 12.73 | 9.96 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
554.57 | (498.69) | 943.64 | (463.91) | |
P/B ratio |
12.04 | 9.31 | 9.84 | 6.08 | |
Price to Tangible BV |
16.82 | 13.26 | 14.43 | 10.67 | |
EV/Sales |
13.51 | 11.46 | 12.86 | 10.12 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8,716.70) | (718.34) | (441.27) | (225.08) | |
EV/FCF |
(678.98) | (180.03) | (167.07) | (107.54) | |
Quick Ratio |
4.15 | 4.43 | 3.82 | 4.26 | |
Current Ratio |
5.04 | 5.43 | 4.69 | 5.20 | |
Net Debt/EBITDA |
30.16 | 29.18 | 1.66 | 30.75 | |
Debt/Assets |
7.32% | 7.58% | 7.62% | 6.85% | |
Debt/Equity |
0.10 | 0.10 | 0.10 | 0.09 | |
Asset Turnover |
0.64 | 0.59 | 0.54 | 0.49 | |
Operating CF/Net income |
(0.81) | 0.63 | (0.05) | 0.62 | |
Capex/Depreciation |
(0.27) | (0.31) | (0.23) | (0.17) | |
Interest Coverage |
(11.83) | (17.65) | (122.05) | (13.93) | |
Research and Development Expense of Revenue |
28.45% | 29.32% | 30.50% | 28.51% | |
Selling, General and Administrative Expense of Revenue |
62.53% | 61.73% | 66.17% | 62.15% | |
Intangible Assets out of Total Assets |
0.21 | 0.22 | 0.23 | 0.33 | |
Share Based Compensation of Revenue |
15.55% | 12.71% | 12.09% | 11.17% | |
Graham Net Nets |
0.03 | 0.04 | 0.04 | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.33%) | (3.05%) | (2.89%) | (1.89%) | |
Free Cash Flow Yield |
(0.15%) | (0.56%) | (0.60%) | (0.94%) | |
Revenue per Share |
3.16 | 2.60 | 2.50 | 2.33 | |
Operating CF per Share |
0.25 | (0.22) | 0.12 | (0.18) | |
Capex per Share |
(0.05) | (0.07) | (0.05) | (0.03) | |
Free Cash Flow per Share |
0.21 | (0.28) | 0.07 | (0.20) | |
Cash per Share |
4.87 | 4.77 | 4.87 | 4.77 | |
Shareholders Equity per Share |
11.60 | 11.56 | 11.47 | 13.41 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.60 | 11.56 | 11.47 | 13.41 | |
Free Cash Flow |
12.09 | (16.48) | 3.93 | (11.72) | |
Working Capital |
413.45 | 396.34 | 373.71 | 367.25 | |
Capital Expenditures |
(2.74) | (3.96) | (2.91) | (1.63) | |
Net Current Asset Value |
277.74 | 263.36 | 237.65 | 224.93 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.03 | 0.02 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
110.94 | 95.61 | 84.68 | 77.55 | |
Average Payables |
16.41 | 17.49 | 18.83 | 15.49 | |
Average Inventory |
61.96 | 60.92 | 60.62 | 61.88 | |
Average Assets |
953.74 | 929.75 | 934.12 | 962.96 | |
Average Common Equity |
723.80 | 717.44 | 711.54 | 719.03 |
Columns are period end dates